The multifunctional and multi-system influence of Ghrelin in the treatment of diabetic and spinal cord injury induced Neuropathy

DP Fields,1 SS Miranpuri,2 GS Miranpuri,1 DK Resnick1

1 Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, 2 Department of Orthopedic Surgery, Division of Podiatric Surgery, Detroit Medical Center, Detroit, MI, USA

ABSTRACT

Ghrelin (Gh), a small peptide, which was originally discovered as a gastrointestinal (GI) tropic hormone, has shown to have a presence and function within multiple tissue systems. Recently, Gh has shown to exhibit anti-inflammatory and regenerative abilities in response to both chemical and mechanical stressors within neural tissues. By continuing to elucidate the potential applications of Gh on pathological neural states, the viability of this peptide hormone for therapeutic uses can be explored for future clinical application.

KEYWORDS: Gastrointestinal peptide hormone, Anti-inflammatory, Neuropathic pain, Neural apoptosis

Corresponding Author: DK Resnick, M.D. Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
E-mail: resnick@neurosurgery.wisc.edu

doi: 10.5214/ans.0972.7531.1118309

Neuropathy: A general overview

Neuropathy (NP) is a unique process that involves the death or damage of nerve cells in the peripheral or central nervous systems as a result of a physical, chemical or electrical stimulus. The resultant effects of neuropathy vary greatly and encompass a wide spectrum of symptoms ranging from the complete loss of function of downstream muscles to the hypersensitivity of tissues in response to marginal levels of stimuli. Although this process has been extensively studied for many decades, the mechanism in which cells undergo natural and stress response neuropathies has yet to be determined definitively. The complexity behind this process can be accredited to the wide range of methods in which neuropathy can be induced, as well as, the many systems that are affected through its initiation. To further compound the ambiguous nature of the issue, there is an eclectic mix of symptoms that an individual suffering from neuropathy may display: tiredness, mechanical hypo and hypersensitivity, unregulated muscle stimulation, thermo hypersensitivity and most notably a lowered threshold for pain induction through nociception stimulation. This lowered threshold can result in a lowered tolerance to marginal introduction of mechanical stressors or in the worst of cases, a continuous state of NP prompted pain followed by the eventual loss of both sensory and motor function.

Several trials have proven successful in discovering different therapeutic methods which are effective in targeting the underlying mechanisms of neuropathic pain. These studies have shown promise, both within in-vitro studies as well as several rat model in-vivo studies, but have not been shown to be effective for long-term large sample size human trials. The inconsistency of these model systems to human trials has proven to be a barrier in treating NP. By continuing to isolate specific components of NP for targeted treatment, there is hope that a better understanding of the mechanisms that lead to NP can lead to a more promising treatment.

To further categorize NP, many clinical researchers address this disease as either acute or chronic in nature. Acute NP involves a short-term sensation, which traditionally leads to a moderate level of neural regeneration that is accompanied by a nearly complete return of normal neural function. Conversely, chronic pain involves prolonged damage that ends with minimal or no regeneration of symptomatic tissues. As a result, chronic NP pain has a higher likelihood of life altering and long term complications. Although there are many causes of NP, two common causes of chronic neuropathy, as well as the focus of this review, are diabetic neuropathy (DN) and chronic contusion injury (CCI) NP. The potential application of the peptide hormone Gh will also be discussed in relation to these to NP states.

Diabetic Neuropathy: mechanism of action and related symptoms

DN is one of the most widespread diseases affecting several regions worldwide. Many countries, including India, have already begun to experience the detrimental effects of DN while other western society countries are projected to have a dramatic increase in patient diagnosis due to the high prevalence of related risk factors. Historically, the indefinite mode of induction of DN has limited the research potential in finding a treatment. Now that the mechanism of action is better understood, studies are establishing the sequence of events that ultimately lead to the clinical presentation of DN. These studies are laying the groundwork for the potential reduction and inhibition of DN related symptoms through metabolic and tissue specific therapeutic agents.

One hypothesis for the clinical presentation of DN involves the accumulation of carbohydrate derivatives in response to hyperglycemia. To summarize, while in the hyyperglycemic state the body begins storing the accumulated glucose as sorbitol through the actions of the enzyme aldose reductase. This glucose to sorbitol reduction is important in DN because it requires the utilization of coenzyme NADPH, an essential substrate for the reaction that demands the presence of coenzyme NADPH, an essential substrate for several other biological processes. When utilized for minimal sorbitol synthesis this reaction causes no adverse side effects; however, when relied upon as a major control mechanism in reducing chronically elevated blood glucose levels this conversion quickly exhausts the supply of NADPH thereby inhibiting other necessary reactions (Fig. 1). One important reaction that demands the presence of NADPH is the use of this coenzyme as the regenerating factor for glutathione. Glutathione is an important element in regulating reactive oxidative species (ROS) of...
aerobic tissues. If not restrained to low levels, these ROS have detrimental effects on cell stability and can lead to apoptosis of neural cells and demyelination of neural tissue via the death of supportive glial cells. Once damage to the neural or glial cells occurs, microglia cells begin the induction of inflammation, which further compounds the damage by inducing apoptosis of various cells. This immune induced apoptosis disrupts signaling processes, which develops into the improper coordination of both sensory and motor signaling leading to the classical symptoms of NP that were discussed above.

The inflammation response that is believed to mediate the apoptosis of neural tissues is thought to depend on the presence of several essential pro-inflammatory cytokines IL-1, IL-6 and TNF-α. Several studies have shown the increased presence of these specific cytokines in relation to chemical induced apoptosis of neuronal tissues. A treatment that targets these specific cytokines may have the potential to inhibit the microglia induced apoptosis and in coordination of neuronal processes that is believed to be at the center of DN.

Spinal Cord Neuropathy: mechanism of action and related symptoms

Although there are an extensive variety of spinal cord neuropathy systems, which operate through several mechanisms, this review will focus on the CCI model and its effects on chronic pain stimulation. The CCI model involves the introduction of a contusion to the dorsal horn in order to simulate blunt force spinal cord lesion. On the cellular level, the similar microglia mediated apoptosis begins the disruption of neuronal signaling and leads to the immediate incoordination of both sensory and motor functioning. This disturbance clinically presents itself as hypersensitivity to external stimuli as well paralysis of caudal muscle tissues. When correlated with the DN system, the cellular apoptosis may also play a key role in the induction of peripheral pain as the loss of myelin directly effects the functioning of the sensory neurons. At the molecular level, shortly following the contusion, spinal cord neuropathy begins to take place as gamma-aminobutyric acid (GABA) inhibitory effects begin to decrease as shown through the reduction of decarboxylase 65 and 67 mRNA expression. The loss of GABA signaling causes a lack of nociceptor inhibition which is essential when down regulating peripheral pain within normally functioning tissues. Although this has yet to be completely resolved, studies have shown through the use of Gabapentin, a GABA analogue, that the introduction of hypersensitivity to mechanical and thermo stimulus in a variety of neuropathic syndromes is strongly associated to the deterioration of GABAAergic receptor presence. The loss of this essential inhibition is believed to enable once insignificant membrane depolarizations to go unregulated and through signal summation cause hypersensitivity to both mechanical and temperature stimulants. To summarize, the loss of GABA inhibition following CCI allows for both the elevation of action potential intensity as well as an increase in neural stimulation. Both of these mechanisms of unregulated neural signaling leads to the introduction of nociceptor induced pain activity.

Another perspective involving the GABA induced inhibition focuses on a study by Wallace et al. in which a contusion onto the spinal column causes a reduction in signal inhibition without a corresponding reduction in GABA receptors. The findings from this study suggest that the decrease in inhibitory post synaptic currents (ISPCs) following a contusion to the spinal cord is not due to the regression of GABA receptors, but rather a transformation of its activity and resultant function. Pitcher et al. focused on this observation as it linked the activities of Na+-K+-Cl co-transporter isoform 1 (NKCC1) and antagonist K+-Cl co-transporter 2 (KCC2) expression to the change in GABAAergic response. Pitcher hypothesizes that the overexpression of the ion pump NKCC1 in transporting chloride ions out of the neuron and the regression of the ion pump KCC2 in the removal of chloride ions out of the neuron following neural tissue inflammation causes the once inhibitory activity of GABA to become excitatory upon binding with its GABAA receptor (Fig. 2). This change in flux has been shown to be characteristic of CCI cases and is postulated to be a key cause of both primary and secondary hyperalgesia. Although the location of these ion channels has yet to be definitively determined, they are believed to be located within the interneurons, C/D pain fibers or the sensory tract leading to the thalamus, which would allow for the change in activity to directly affect key pain signaling processes. As of right now the channels have been determined to be in the CNS spinal tissue with indefinite cell discrimination.

Fig 1: Proposed mechanism for neural demyelination in Diabetic Neuropathy. The shunting of NADPH from the glutathione recycling process limits the reduction of ROS within the aerobic neural tissue. A build-up of ROS causes demyelination of neurons as well as the induction of inflammation from the resultant cell damage.
the therapeutic use of Gabapentin had shown to have potential in the treatment of hyperalgesia. Pitcher’s study indicates that GABA action is creating a depolarization effect due to the presence of several key membrane pumps while the Gabapentin study had shown the effectiveness of Gabapentin in reducing hyperalgesia following CCI. One possible cause for this discrepancy is the delay time allowed for each individual study. The Gabapentin study focused on individuals with prolonged pain (3 months) while Pitcher began his study to assess NKCC1’s implications shortly after the introduction of injury. When taken together the two studies suggest a dichotomous origin of pain, which is dependent on a similar loss of signal inhibition that is caused by two distinctly separate mechanisms. One being caused by reversal of a previously inhibitory signal while the other being caused by regression of signal activation. Although there is no definite explanation as to the change in causes for hypersensitivity within these two studies, factors such as this add to the complications that delay the discovery of a long-term treatment of CCI induced NP. These studies suggest that there is both a short term and long-term molecular change, which individually cause hyperalgesia. Although not yet resolved, it suggests the need of a multiple phase treatment method, which accommodates to the changing cause of hyperalgesia or prevents late onset while treating the early molecular changes.

**Ghrelin: newly discovered applications**

Gh, a gastrointestinal derived protein hormone, was originally discovered as a ligand that interacts with its analogous receptor, growth hormone secretagogue receptor (GHS-R), to regulate the fluidity between the fed and fasting states. Although Gh is secreted predominantly from the stomach and the receptors are mostly concentrated within the hypothalamus, both the receptor and peptide hormone have recently been found to exist ubiquitously within various mammalian organ systems. Although predominantly present in the deacetylated form in circulation, only the acetylated form has shown to interact with the GHS-R while the deacylated form is believed to be either an inactive pro-hormone or deactivated hormone state.

Several recent studies, which have looked into trace expression of acetylated Gh within tissues unrelated to digestion and homeostasis regulation have prompted investigations into other potential sites and purposes of Gh activity (Fig. 3). One function in particular is centered on work which has shown Gh to have the ability to counteract inflammatory signals that are known to interrupt proper neural signaling through neural tissue apoptosis. The application of Gh, in-vitro and in-vivo, has shown to specifically inhibit apoptotic processes induced by cytokines IL-1 and TNF-α, (as well as several other cytokines) which are normally active within damaged neural tissues. Studies such as the one by Lee showed that Gh can work with its receptor in order to prevent oligodendrocyte damage from reactive oxygen species, similar to what is believed to cause DN. Although interaction with GHS-R has shown to be beneficial when utilizing Gh’s effects, another study by Bulgarelli shows an implication for ghrelin to work independently of its GHS-R receptor upon CD36 receptors of microglia cells to prevent their activation and pro-inflammatory response. The lack of need for GHS-R has allowed for Gh to be applied to neural, glia and immune cells that may not express RNA for GHS-R but rather any cell that merely interacts with microglia, a common neural immune cell.

In addition to the inhibition of pro-inflammatory signals, Gh’s also functions as a stimulant to T-regulator cells through the promotion of the cytokine IL-10. This is beneficial when regulating inflammation because T-cells are instrumental in the inactivation of already present inflammatory responses and thus act indirectly as an anti-inflammatory cytokine as they inhibit further microglia activation. T regulatory cells specifically reduce the effects of Th-1 mediated cytotoxic cells which when contacted by damaged tissue, induce apoptosis of both neurons and glia cells. The elimination of the TH-1 pathway during neural cell damage helps IL-10 and subsequently Gh function as a neural protective agent for tissues that are exposed to a stressor, which has a tendency to promote apoptosis, or controlled tissue salvaging, such as the case in both DN and CCI.

Finnaly, the presence of GHS-R within deep dorsal horn regions of the spinal cord have been shown to have an inhibitory effect on nociceptor stimulation. The exact mechanism has yet to be determined but the interaction of Gh with GHS-R has shown to decrease the expres-
sion of c-Fos, a secondary messenger which is often utilized as a marker to indicate recent neuronal stimulation, within which is often utilized as a marker to induction of c-Fos, a secondary messenger.

**Promotion of T cell regulating cytokine IL-10 inhibit the differentiation of cytotoxic T cells C) inhibition of TNF-α also inhibits cytotoxic T cell induced apoptosis.**

**Future Outlook**

Gh’s function as a general anti-inflammatory agent through the inhibition of common inflammation signaling pathways has allowed for it to be applied to a variety of NP states that often function through common means, such as DN’s and CCF’s shared utilization of cytokine induced apoptosis to compensate for chemical and mechanical stressors respectively. By recognizing and exploring the similarities between these two neuropathy states as well as applying the newly evolved discoveries of Gh to other neural disease systems with similar mediators, the use of Gh can be foreseen to transition between various NP states interchangeably as a general therapeutic agent to combat inflammation induced apoptosis.

The article complies with International Committee of Medical Journal Editor’s uniform requirements for the manuscripts.

Competing interests – None, Source of Funding – None

Received Date : 22 May 2011

Revised Date : 17 June 2011

Accepted Date : 8 July 2011

**References**

1. Fear C. Neopathic pain: Clinical features, assessment and treatment. Nurs Stand 2010; 25: 35-40.

2. Serra J, Solà R, Aleu J, et al. Double and triple spikes in c-nociceptors in neuropathic pain states: An additional peripheral mechanism of hyperalgesia. Pain 2011; 152(2): 343-353.

3. Schwartzman R and Maleki J. Post Injury neuropathic pain syndromes. Med Clin North Am 1999; 83: 597-626.

4. Taylor, B. The pathophysiology of neuropathic pain. Neurosurgical Pain Management 2004; 29-37.

5. Vadakkan K and Xu Hu. Common characteristics and pathways in neuropathic pain of etiologies. Drug Discov Today Dis Models 2006; 3: 413-417.

6. Zimmerman M. Pathobiology of neuropathic pain. Euro J Pharmacol 2001; 429: 23-27.

7. Holtman JR Jr, Crooks PA, Johnson-Hardy J, et al. Antinociceptive effects and toxicity of morphine-6-O-sulfate sodium salt in rat models of pain. Euro J Pharmacol 2010; 648: 87-94.

8. Melli G and Hoke A. Dorsal root ganglion sensory neuronal cultures: a tool or drug discovery for peripheral neuropathies. Expert Opin Drug Discov 2009; 4: 1035-1045.

9. Ossipov M and Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRX 2005; 2: 650-661.

10. Yagihashi S, Yamagishi S and Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77: 5184-189.

11. Tahrani AA, Askwith T and Stevens MJ. Emerging drugs for diabetic neuropathy. Expert Opin Emerg Drugs 2010; 15: 661-683.

12. Petit W and Upender R. Medical evaluation and treatment of diabetic peripheral neuropathy. Clin Podiatr Med Surg 2003; 20: 671-688.

13. Greene D, Stevens M, Obrosova I, et al. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Euro J Pharmacol 1999; 375: 217-233.

14. Anderson K, Seed T and Harris J. Free radicals and reactive oxygen species in programmed cell death. Med Hypotheses 1999; 52: 451-463.

15. Talbot S, Chahmi E, Dias J, et al. Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J Neuroinflammation 2010; 7: 36.

16. King GL. The role of inflammatory cytokines in diabetes and its complications. J Peridontol 2008; 79: 1527-1534.

17. Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation in the lumbar sacral spinal cord decreases detrusor over activity in spinal cord injured rats. J Urol 2008; 179: 1178-1183.

18. Moore K, Kohno T, Karchewsky LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in superficial dorsal horn of the spinal cord. J Neurosci 2002; 22: 6724-6731.

19. Wallace MS, Irving G and Cowles VE. Gabapentin extended release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double blind, placebo controlled, multicenter study. Clin Drug Invest 2010; 30: 765-776.

20. Bar Ad V. Gabapentin for treatment of cancer related pain syndromes. Rev Recent Clin Trials 2010; 5(3): 174-178.

21. T Hasbargen, Ahmed M, Miranpuri G, et al. Role of NKCC1 and KCCE2 in the development of chronic neuropathic pain following spinal cord injury. Ann N Y Acad Sci 2010; 1198: 168-172.

22. Pitcher MH and Cervero F. Role of NKCC1 co-transporter in sensitization of spinal nociceptive neurons. Pain 2010; 151: 756-762.
23. Liedtke CM and Cole TS. Activation of NKCC1 by hyperosmotic stress in human tracheal epithelial cells involves PKC-delta and ERK. Biochim Biophys Acta 2002; 1589(1): 77-88.

24. Cramer SW, Baggott C, Cain J, et al. The role of cation dependent chloride transporters in neuropathic pain following spinal cord injury. Mol Pain 2008; 17: 4: 36.

25. Kojima M and Hosoda H. Ghrelin is a growth hormone releasing acetylated peptide from the stomach. Nature 1999; 402: 656-660.

26. Guneli E, Kazikdas K and Kolatan E. Ghrelin may attenuate pro-inflammatory cytokine-mediated neuropathic pain. Med Hypothesis 2007; 69(2): 356-360.

27. Guneli E, Onal A, Ates M, et al. Effects of repeated administered ghrelin on chronic constriction injury of sciatic rats. Neurosci Lett 2010; 479(3): 226-230.

28. Lee JY, Chung H, Yoo YS, et al. Inhibition of apoptotic cell death by ghrelin improves functional recovery after spinal cord injury. Endocrinology 2010; 151(8): 3815-3826.

29. Lee JY, Oh TH and Yune TY. Ghrelin inhibited hydrogen peroxide-induced apoptotic cell death of oligodendrocytes via ERK and p38MAPK signaling. Endocrinology 2011; 152(6): 2377-2386.

30. Bulgarelli I, Tamiazzo L, Bresciani E, et al. Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res 2009; 87(12): 2718-2727.

31. Vergnano A, Ferrini F, Salio C, et al. The gastrointestinal hormone ghrelin modulates inhibitory neurotransmission in deep laminea in mouse spinal cord dorsal horn. Endocrinology 2008; 149(5): 2306-2312.

32. Inoue Y, Nakahara K, Kangawa K, et al. Translational change in rat fetal cell proliferation in response to ghrelin and des-acyl ghrelin during the late stage of pregnancy. Biochem Biophys Res Commun 2010; 393(3): 455-460.